Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis

Philipp Saiko, Maria Ozsvar-Kozma, Geraldine Graser, Andreas Lackner, Michael Grusch, Sibylle Madlener, Georg Krupitza, Walter Jaeger, M. Hídvégi, Ramp P. Agarwal, Monika Fritzer-Szekeres, Thomas Szekeres

Research output: Article

9 Citations (Scopus)

Abstract

Avemar (MSC) is a nontoxic fermented wheat germ extract, which has been shown to significantly improve the survival rate in patients suffering from various malignancies. We investigated its effects in sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells. After 48 and 72 h of incubation, Avemar inhibited the growth of sensitive H9 cells with IC50 values of 290 and 200 μg/ml, whereas the growth of 5-FdUrd/Ara-C cross-resistant H9 cells was attenuated with IC50 values of 180 and 145 μg/ml, respectively. Treatment with 300 μg/ml MSC for 48 h caused dosedependent induction of apoptosis in 48% of sensitive H9 cells. In cross-resistant H9 cells, incubation with 200 μg/ml Avemar for 48 h led to 41% of apoptotic tumor cells. Growth arrest of sensitive H9 cells after exposure to various concentrations of MSC occurred mainly in the S phase of the cell cycle, thereby increasing the cell population from 54 to 73% while depleting cells in the G0-G1 phase from 40 to 19%. Growth arrest in cross-resistant H9 cells occurred also mainly in the S phase, increasing the cell population from 45 to 68% while depleting cells in the G0-G1 phase from 45 to 31%. As MSC treatment likely overcomes 5-FdUrd/Ara-C resistance, further investigations to elucidate the exact mechanisms are warranted. We conclude that Avemar exerts a number of beneficial effects which could support conventional chemotherapy of human malignancies.

Original languageEnglish
Pages (from-to)787-791
Number of pages5
JournalOncology Reports
Volume21
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Cytarabine
Lymphoma
Apoptosis
Growth
Cell Cycle Resting Phase
G1 Phase
S Phase
Inhibitory Concentration 50
Avemar
Neoplasms
Population
Cell Cycle
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis. / Saiko, Philipp; Ozsvar-Kozma, Maria; Graser, Geraldine; Lackner, Andreas; Grusch, Michael; Madlener, Sibylle; Krupitza, Georg; Jaeger, Walter; Hídvégi, M.; Agarwal, Ramp P.; Fritzer-Szekeres, Monika; Szekeres, Thomas.

In: Oncology Reports, Vol. 21, No. 3, 2009, p. 787-791.

Research output: Article

Saiko, P, Ozsvar-Kozma, M, Graser, G, Lackner, A, Grusch, M, Madlener, S, Krupitza, G, Jaeger, W, Hídvégi, M, Agarwal, RP, Fritzer-Szekeres, M & Szekeres, T 2009, 'Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis', Oncology Reports, vol. 21, no. 3, pp. 787-791. https://doi.org/10.3892/or_00000285
Saiko, Philipp ; Ozsvar-Kozma, Maria ; Graser, Geraldine ; Lackner, Andreas ; Grusch, Michael ; Madlener, Sibylle ; Krupitza, Georg ; Jaeger, Walter ; Hídvégi, M. ; Agarwal, Ramp P. ; Fritzer-Szekeres, Monika ; Szekeres, Thomas. / Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis. In: Oncology Reports. 2009 ; Vol. 21, No. 3. pp. 787-791.
@article{3eed6163140948b6968b622a54275fe1,
title = "Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis",
abstract = "Avemar (MSC) is a nontoxic fermented wheat germ extract, which has been shown to significantly improve the survival rate in patients suffering from various malignancies. We investigated its effects in sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells. After 48 and 72 h of incubation, Avemar inhibited the growth of sensitive H9 cells with IC50 values of 290 and 200 μg/ml, whereas the growth of 5-FdUrd/Ara-C cross-resistant H9 cells was attenuated with IC50 values of 180 and 145 μg/ml, respectively. Treatment with 300 μg/ml MSC for 48 h caused dosedependent induction of apoptosis in 48{\%} of sensitive H9 cells. In cross-resistant H9 cells, incubation with 200 μg/ml Avemar for 48 h led to 41{\%} of apoptotic tumor cells. Growth arrest of sensitive H9 cells after exposure to various concentrations of MSC occurred mainly in the S phase of the cell cycle, thereby increasing the cell population from 54 to 73{\%} while depleting cells in the G0-G1 phase from 40 to 19{\%}. Growth arrest in cross-resistant H9 cells occurred also mainly in the S phase, increasing the cell population from 45 to 68{\%} while depleting cells in the G0-G1 phase from 45 to 31{\%}. As MSC treatment likely overcomes 5-FdUrd/Ara-C resistance, further investigations to elucidate the exact mechanisms are warranted. We conclude that Avemar exerts a number of beneficial effects which could support conventional chemotherapy of human malignancies.",
keywords = "Apoptosis, Avemar (MSC), Cell cycle, Growth inhibition, Sensitive and 5-FdUrd/Ara-C crossresistant H9 human lymphoma cells",
author = "Philipp Saiko and Maria Ozsvar-Kozma and Geraldine Graser and Andreas Lackner and Michael Grusch and Sibylle Madlener and Georg Krupitza and Walter Jaeger and M. H{\'i}dv{\'e}gi and Agarwal, {Ramp P.} and Monika Fritzer-Szekeres and Thomas Szekeres",
year = "2009",
doi = "10.3892/or_00000285",
language = "English",
volume = "21",
pages = "787--791",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis

AU - Saiko, Philipp

AU - Ozsvar-Kozma, Maria

AU - Graser, Geraldine

AU - Lackner, Andreas

AU - Grusch, Michael

AU - Madlener, Sibylle

AU - Krupitza, Georg

AU - Jaeger, Walter

AU - Hídvégi, M.

AU - Agarwal, Ramp P.

AU - Fritzer-Szekeres, Monika

AU - Szekeres, Thomas

PY - 2009

Y1 - 2009

N2 - Avemar (MSC) is a nontoxic fermented wheat germ extract, which has been shown to significantly improve the survival rate in patients suffering from various malignancies. We investigated its effects in sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells. After 48 and 72 h of incubation, Avemar inhibited the growth of sensitive H9 cells with IC50 values of 290 and 200 μg/ml, whereas the growth of 5-FdUrd/Ara-C cross-resistant H9 cells was attenuated with IC50 values of 180 and 145 μg/ml, respectively. Treatment with 300 μg/ml MSC for 48 h caused dosedependent induction of apoptosis in 48% of sensitive H9 cells. In cross-resistant H9 cells, incubation with 200 μg/ml Avemar for 48 h led to 41% of apoptotic tumor cells. Growth arrest of sensitive H9 cells after exposure to various concentrations of MSC occurred mainly in the S phase of the cell cycle, thereby increasing the cell population from 54 to 73% while depleting cells in the G0-G1 phase from 40 to 19%. Growth arrest in cross-resistant H9 cells occurred also mainly in the S phase, increasing the cell population from 45 to 68% while depleting cells in the G0-G1 phase from 45 to 31%. As MSC treatment likely overcomes 5-FdUrd/Ara-C resistance, further investigations to elucidate the exact mechanisms are warranted. We conclude that Avemar exerts a number of beneficial effects which could support conventional chemotherapy of human malignancies.

AB - Avemar (MSC) is a nontoxic fermented wheat germ extract, which has been shown to significantly improve the survival rate in patients suffering from various malignancies. We investigated its effects in sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells. After 48 and 72 h of incubation, Avemar inhibited the growth of sensitive H9 cells with IC50 values of 290 and 200 μg/ml, whereas the growth of 5-FdUrd/Ara-C cross-resistant H9 cells was attenuated with IC50 values of 180 and 145 μg/ml, respectively. Treatment with 300 μg/ml MSC for 48 h caused dosedependent induction of apoptosis in 48% of sensitive H9 cells. In cross-resistant H9 cells, incubation with 200 μg/ml Avemar for 48 h led to 41% of apoptotic tumor cells. Growth arrest of sensitive H9 cells after exposure to various concentrations of MSC occurred mainly in the S phase of the cell cycle, thereby increasing the cell population from 54 to 73% while depleting cells in the G0-G1 phase from 40 to 19%. Growth arrest in cross-resistant H9 cells occurred also mainly in the S phase, increasing the cell population from 45 to 68% while depleting cells in the G0-G1 phase from 45 to 31%. As MSC treatment likely overcomes 5-FdUrd/Ara-C resistance, further investigations to elucidate the exact mechanisms are warranted. We conclude that Avemar exerts a number of beneficial effects which could support conventional chemotherapy of human malignancies.

KW - Apoptosis

KW - Avemar (MSC)

KW - Cell cycle

KW - Growth inhibition

KW - Sensitive and 5-FdUrd/Ara-C crossresistant H9 human lymphoma cells

UR - http://www.scopus.com/inward/record.url?scp=64849114221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64849114221&partnerID=8YFLogxK

U2 - 10.3892/or_00000285

DO - 10.3892/or_00000285

M3 - Article

VL - 21

SP - 787

EP - 791

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 3

ER -